A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
Advanced Cancer
DRUG: CS1001
To evaluate the safety and tolerability of CS1001, From first dose to 30 days after last dose of CS1001, up to 2 years|To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CS1001, From first dose to 30 days after last dose of CS1001, up to 2 years
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.